X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.prnewswire.com/news-releases/epicentrx-announces-presentation-for-phase-2-randomized-active-controlled-multicenter-trial-to-assess-the-safety-and-efficacy-of-rrx-001-vs-regorafenib-in-thirdfourth-line-colorectal-cancer-at-the-2023-american-society-of-clin-301726884.html
https://www.prnewswire.com/news-releases/rrx-001--irinotecan-significantly-improved-progression-free-survival-pfs-versus-regorafenib-in-the-randomized-phase-2-rocket-trial-in-advanced-colorectal-cancer-301702337.html
https://pharmaphorum.com/news/onquality-pharma-raises-15m-for-drug-to-treat-vegf-side-effects/
https://endpts.com/bristol-myers-squibbs-opdivo-couldnt-topple-nexavar-in-hcc-but-will-better-safety-profile-win-over-physicians/
https://www.biopharmadive.com/news/meet-the-protein-responsible-for-nearly-100b-in-cancer-drug-deals/561097/
https://www.biopharmadive.com/news/deciphera-gastrointestinal-cancer-drug-race-blueprint/560808/
https://www.fiercebiotech.com/biotech/deciphera-soars-as-phase-3-cancer-data-tee-up-fda-filing
https://www.contractpharma.com/contents/view_breaking-news/2019-07-18/bayer-bms-ono-to-collaborate-on-colorectal-cancer-treatments/
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/bayers-move-to-block-natcos-colorectal-cancer-brand-dismissed-by-delhi-hc/articleshow/70213026.cms
https://www.fiercepharma.com/pharma/bristol-myers-opdivo-fails-to-beat-nexavar-earlier-use-liver-cancer
https://www.fiercepharma.com/pharma/can-stivarga-crack-code-bayer-hunts-for-rare-glioblastoma-nod-big-5-contender
https://www.prnewswire.com/news-releases/cstone-and-bayer-announce-global-collaboration-to-evaluate-pd-l1-monoclonal-antibody-cs1001-in-combination-with-regorafenib-300864253.html
http://www.pharmatimes.com/news/stivarga_final_nice_recommendation_for_hepatocellular_carcinoma_1274383
https://www.forbes.com/sites/johnlamattina/2018/09/13/can-a-cancer-drug-originated-in-china-be-a-success-in-the-u-s/#60a9a8e2dd54
https://www.fiercepharma.com/marketing/adempas-maker-bayer-connects-hypertension-patients-new-mentoring-group
http://ir.blueprintmedicines.com/phoenix.zhtml?c=253931&p=irol-newsArticle&ID=2355440
http://www.pharmatimes.com/news/five_therapies_endorsed_for_use_on_nhs_scotland_1234655
https://www.fiercepharma.com/pharma/currency-headwind-bayer-s-pharma-meets-expectation-as-consumer-slides-again
http://www.pharmatimes.com/news/liver_cancer_patients_barred_from_nhs_access_to_bayers_stivarga_1221195
http://www.pharmatimes.com/news/bayers_stivarga_wins_nice_approval_for_gist_1211984
http://www.fiercepharma.com/pharma/nice-shoots-down-bayer-s-stivarga-liver-cancer-citing-price-clinical-questions
http://www.pharmafile.com/news/515366/nice-gives-final-draft-guidance-two-key-cancer-drugs
http://www.pharmatimes.com/news/nice_approves_bayers_nexavar_for_primary_liver_cancer_1201174
http://www.pmlive.com/pharma_news/ema_clears_bayers_stivarga_for_liver_cancer_1200536
http://www.pharmamanufacturing.com/industrynews/2017/fda-approves-bayers-stivarga-for-liver-cancer/
https://www.multivu.com/players/English/8002351-bayer-stivarga-fda-approval/?c=y
http://www.press.bayer.com/baynews/baynews.nsf/id/A6E220D8E59FD1C2C12580CF001BD137
http://www.fiercepharma.com/pharma/bayer-s-hefty-2016-pharma-growth-underlines-danger-neglecting-r-d-for-monsanto-buy
http://www.fiercepharma.com/pharma/eisai-s-lenvima-moves-toward-nexavar-showdown-phase-3-liver-cancer-win
http://www.prnewswire.com/news-releases/fda-grants-bayer-priority-review-for-stivarga-regorafenib-for-the-second-line-systemic-treatment-of-liver-cancer-300385164.html
http://www.reuters.com/article/us-bayer-regorafenib-idUSKBN1320VY
http://www.fiercepharma.com/marketing/bayer-counts-nexavar-stivarga-continuum-to-protect-its-liver-cancer-lead
http://www.fiercepharma.com/pharma/california-biotech-hits-bayer-growth-hope-stivarga-ipr-challenge
http://www.fiercepharma.com/pharma/bayer-growth-hope-stivarga-boosts-survival-liver-cancer-patients
http://www.prnewswire.com/news-releases/phase-iii-data-show-bayers-stivarga-regorafenib-improved-overall-survival-in-previously-treated-patients-with-unresectable-liver-cancer-300291238.html
http://www.prnewswire.com/news-releases/bayer-collaborates-with-us-national-surgical-adjuvant-breast-and-bowel-project-nsabp-to-investigate-stivarga-regorafenib-tablets-as-additional-adjuvant-therapy-in-colon-cancer-300277414.html
http://www.fiercepharma.com/pharma/bayer-plots-stivarga-expansion-new-top-line-data-hand
http://in.reuters.com/article/us-bayer-regorafenib-phaseiii-idINKCN0XV28O
http://www.fiercepharma.com/pharma/sanofi-s-weak-q1-cancer-drug-sales-spur-medivation-buyout-desire
http://www.prnewswire.com/news-releases/bayer-to-highlight-latest-stivarga-regorafenib-tablets-research-at-asco-gi-2016-300206600.html
http://portal.anvisa.gov.br/wps/content/anvisa+portal/anvisa/sala+de+imprensa/menu+-+noticias+anos/2015/dois+novos+medicamentos+sao+registrados+pela+anvisa.
http://www.reuters.com/article/2015/10/08/us-usa-healthcare-cancer-insight-idUSKCN0S20DG20151008
http://www.pmlive.com/pharma_news/disappointment_for_pharma_with_new_cancer_drugs_fund_list_743326
Market Place
Share 
